cholestyramine resin has been researched along with niacin in 82 studies
| Studies (cholestyramine resin) | Trials (cholestyramine resin) | Recent Studies (post-2010) (cholestyramine resin) | Studies (niacin) | Trials (niacin) | Recent Studies (post-2010) (niacin) |
|---|---|---|---|---|---|
| 2,669 | 342 | 190 | 11,974 | 462 | 1,488 |
| Protein | Taxonomy | cholestyramine resin (IC50) | niacin (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 0.14 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.14 | |
| Hydroxycarboxylic acid receptor 2 | Homo sapiens (human) | 0.1726 | |
| Hydroxycarboxylic acid receptor 2 | Mus musculus (house mouse) | 0.14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (37.80) | 18.7374 |
| 1990's | 30 (36.59) | 18.2507 |
| 2000's | 16 (19.51) | 29.6817 |
| 2010's | 4 (4.88) | 24.3611 |
| 2020's | 1 (1.22) | 2.80 |
| Authors | Studies |
|---|---|
| Grundy, SM | 1 |
| McIntyre, TH; Shapiro, ML; Whitney, EJ; Wirebaugh, SR | 1 |
| Erkelens, DW | 1 |
| Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK | 1 |
| Miller, NE | 1 |
| Stoy, DB | 1 |
| Kostner, GM | 1 |
| Anding, RH; Lueg, MC | 1 |
| Angelin, B; Einarsson, K; Eriksson, M | 1 |
| Ritter, KS | 1 |
| Kane, JP; Malloy, MJ | 2 |
| Naito, HK | 1 |
| Stein, EA | 1 |
| Davignon, J | 1 |
| Blum, CB; Levy, RI | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Havel, RJ; Kane, JP | 2 |
| Gotto, AM; Jones, PH; Scott, LW | 1 |
| Brewer, HB; Hoeg, JM; Starzl, TE | 1 |
| Packard, CJ; Shepherd, J | 1 |
| Bailey, KR; Brewer, HB; Hoeg, JM; Maher, MB | 1 |
| Stuyt, PM | 1 |
| Levy, RI; Schaefer, EJ | 1 |
| Gibson, P; Lloyd, J; West, R | 1 |
| Parker, F | 1 |
| Bakke, OM; Berge, RK | 1 |
| Stamler, J | 1 |
| Barthel, U; Haller, H; Hanefeld, M; Hora, C; Rothe, G; Schulze, J | 1 |
| Nash, DT | 1 |
| Azarnoff, DL; Saunders, RN | 1 |
| Ginsberg, HN | 1 |
| Gotto, AM; Yeshurun, D | 1 |
| Chin, MM; Jozefiak, E; Morales, E; Spinler, SA; Wilson, MD | 1 |
| Coates, PM; Cortner, JA; Jarvik, GP; Liacouras, CA | 2 |
| Farmer, JA; Gotto, AM | 2 |
| Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH | 1 |
| Hodgson, JM; Marks, SJ; Matthews, PG; Myers, KA; Wahlqvist, ML | 1 |
| Hwang, DS; Jokubaitis, LA; Robinson, WT; Smith, HT; Troendle, AJ | 1 |
| McKenney, JM | 1 |
| Nakamura, H; Takahashi, Y | 1 |
| Abel, RB; Argoff, CE; Di Bisceglie, AM; Grewal, RP; Higgins, JJ; Parker, CC; Patterson, MC; Pentchev, PG; Schiffmann, R; Yu, K | 1 |
| Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
| Jokubaitis, LA | 2 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Andrews, TC; Green, G; Kalenian, R; Personius, BE; Whitney, EJ | 1 |
| Hoogerbrugge, N | 1 |
| Gordon, BR; Saal, SD | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Linderer, T; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Chin-Dusting, JP; Shaw, JA | 1 |
| Bhatnagar, D | 1 |
| Anderson, LM; Calvert, RJ; Diwan, BA; Kritchevsky, D; Ramakrishna, G; Tepper, S | 1 |
| Anderson, LM; Calvert, RJ; Diwan, BA; Kritchevsky, D; Tepper, S | 1 |
| TENNENT, DM; ZANETTI, ME | 1 |
| Kashyap, ML; Malik, S | 1 |
| Charlotte, N; Sani, M | 1 |
| Brown, BG; Gotto, AM; Kolasa, MW; Krasuski, RA; Maranian, AM; Michalek, JE; Monick, E; Personius, BE; Whitney, EJ | 1 |
| Foley, SM | 1 |
| Birbeck, GL; Jacobs, BS; Kothari, RU; Maddox, K; Mullard, AJ; Reeves, MJ; Stoeckle-Roberts, S; Wehner, S | 1 |
| Balbisi, EA | 1 |
| Anderson, LM; Calvert, RJ; Kammouni, W; Kritchevsky, D; Tepper, S | 1 |
| Hashemi, MJ; Hekmat, M; Kouhi, A; Mojtahedzadeh, S; Naderi, N; Nobahar, R; Rafeiyian, S | 1 |
| Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ | 1 |
| Devendra, GP; Krasuski, RA; Whitney, EJ | 1 |
| Cater, G; Devendra, GP; Krasuski, RA; Whitney, EJ | 1 |
| Jacobson, TA | 1 |
| Chen, L; Chen, SC; Tsui, L; Wu, SJ; Xie, W; Xu, S; Ye, P | 1 |
27 review(s) available for cholestyramine resin and niacin
| Article | Year |
|---|---|
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol | 1992 |
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit Analysis; Drug Therapy, Combination; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol; Sensitivity and Specificity | 1990 |
Pharmacological intervention for altering lipid metabolism.
Topics: Animals; Cholestyramine Resin; Coronary Disease; Gemfibrozil; Humans; Lipid Metabolism; Lipids; Niacin | 1990 |
The affection of lipoprotein-a by lipid lowering drugs.
Topics: Arteriosclerosis; Bezafibrate; Cholestyramine Resin; Hormones; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins; Neomycin; Niacin; Nicotinic Acids; Stanozolol | 1988 |
When to treat hyperlipidemia.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Neomycin; Niacin; Pentanoic Acids; Risk Factors; Triglycerides | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Niacin; Patient Education as Topic; Pentanoic Acids; Probucol | 1987 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Mice; Middle Aged; Neomycin; Niacin; Pentanoic Acids; Pregnancy; Probucol; Rats | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides | 1986 |
Pharmacological modification of lipoprotein metabolism.
Topics: Animals; Bile Acids and Salts; Cholestyramine Resin; Clofibrate; Colestipol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Absorption; Lipoproteins; Niacin; Sterols | 1987 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylomicrons; Colestipol; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Hypobetalipoproteinemias; Hypolipoproteinemias; Infant; Infant, Newborn; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Tangier Disease | 1985 |
Treatment of hypercholesterolemia.
Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Neomycin; Niacin; Nicotinic Acids; Probucol; Sitosterols; Thyroxine | 1982 |
Therapy of hyperlipidemic states.
Topics: Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Colestipol; Dietary Fats; Drug Therapy, Combination; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins, LDL; Lipoproteins, VLDL; Niacin; Nicotinic Acids; Sitosterols | 1982 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Neomycin; Niacin; Nicotinic Acids; Probucol; Sitosterols | 1982 |
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Topics: Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Coronary Disease; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin | 1995 |
Hyperlipidemia: perspectives in diagnosis and treatment.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Restricted; Diet, Reducing; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol; Risk; Triglycerides | 1995 |
Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management.
Topics: Adolescent; Adult; Biological Transport; Child; Child, Preschool; Cholestyramine Resin; Diet, Fat-Restricted; Humans; Hyperlipidemia, Familial Combined; Lipoproteins; Lovastatin; Niacin | 1994 |
Antihyperlipidaemic agents. Drug interactions of clinical significance.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibric Acid; Colestipol; Drug Interactions; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Probucol | 1994 |
Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management.
Topics: Adolescent; Apolipoproteins B; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Combined Modality Therapy; Coronary Disease; Energy Intake; Female; Genetic Linkage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipoproteins, VLDL; Liver; Male; Multigene Family; Niacin; Phenotype; Polymorphism, Genetic; Triglycerides | 1993 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides | 1996 |
Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Niacin; Nutritional Physiological Phenomena; Probucol | 2001 |
Should pediatric patients with hyperlipidemia receive drug therapy?
Topics: Anticholesteremic Agents; Child; Cholestyramine Resin; Coronary Disease; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Psyllium; Risk Assessment | 2002 |
Dyslipidemia treatment: current considerations and unmet needs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin | 2003 |
Update on risk factors for atherosclerosis: the role of inflammation and apolipoprotein E.
Topics: Apolipoproteins E; Arteriosclerosis; Cholestyramine Resin; Diet, Fat-Restricted; Exercise; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Internal Medicine; Life Style; Lipoproteins; Niacin; Nurse's Role; Nursing Assessment; Perioperative Nursing; Risk Assessment; Risk Factors; Specialties, Nursing; Tunica Intima | 2005 |
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors | 2006 |
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome | 2010 |
Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.
Topics: Apolipoproteins B; Bile Acids and Salts; Cardiovascular Diseases; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Randomized Controlled Trials as Topic; Risk Assessment | 2011 |
16 trial(s) available for cholestyramine resin and niacin
| Article | Year |
|---|---|
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol | 1992 |
Pharmacological trials: primary and secondary prevention of coronary heart disease.
Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dipyridamole; Estrogens; Humans; Hypercholesterolemia; Male; Middle Aged; Niacin; Sulfinpyrazone | 1983 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Neomycin; Niacin; Nicotinic Acids; Probucol; Sitosterols | 1982 |
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Lipids; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome | 1994 |
Pharmacokinetics of fluvastatin and specific drug interactions.
Topics: Adolescent; Adult; Aged; Aging; Biological Availability; Cholestyramine Resin; Diet; Digoxin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Propranolol; Sex Characteristics; Time Factors; Triglycerides | 1993 |
The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Dimethyl Sulfoxide; Drug Therapy, Combination; Humans; Liver; Lovastatin; Male; Niacin; Niemann-Pick Diseases | 1993 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Niacin; Reference Values; Vasodilation | 1997 |
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Prospective Studies; Treatment Outcome | 1999 |
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemoprevention; Chi-Square Distribution; Cholesterol, LDL; Cholestyramine Resin; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Drug Combinations; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Niacin; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Regression Analysis; Statistics, Nonparametric; Stroke; Survival Rate; Treatment Outcome | 2000 |
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin | 2005 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1994 |
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholestyramine Resin; Coronary Artery Disease; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipoproteins, HDL; Male; Middle Aged; Niacin; Risk; Risk Factors; Treatment Outcome; Young Adult | 2010 |
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
Topics: Aged; Anticholesteremic Agents; Body Mass Index; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Lipids; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Military Personnel; Niacin; Treatment Outcome | 2011 |
42 other study(ies) available for cholestyramine resin and niacin
| Article | Year |
|---|---|
A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin.
Topics: Aged; Alanine Transaminase; Cholestyramine Resin; Colestipol; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipids; Lovastatin; Male; Middle Aged; Niacin; Retrospective Studies | 1992 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Lovastatin; Neomycin; Niacin; Probucol | 1991 |
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Niacin; Simvastatin | 1990 |
Controlling cholesterol with drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hypercholesterolemia; Lovastatin; Niacin | 1989 |
Hypercholesterolemia: new values, new strategies.
Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Coronary Disease; Energy Intake; Female; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin | 1986 |
Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition.
Topics: Adult; Bile; Bile Acids and Salts; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Niacin | 1986 |
Steinernema feltiae (= Neoaplectana carpocapsae): effect of sterols and hypolipidemic agents on development.
Topics: Animals; Anticholesteremic Agents; Caseins; Cholesterol; Cholestyramine Resin; Clofibrate; Culture Media; Dextrothyroxine; Female; Globulins; Hemin; Hydrogen-Ion Concentration; Male; Moths; Myoglobin; Nematoda; Niacin; Sterols | 1988 |
Drug therapy in children and adolescents with familial hypercholesterolemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Male; Niacin | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Dietary Fats; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Niacin; Patient Compliance; Pentanoic Acids; Probucol; Risk Factors | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pentanoic Acids; Phenols; Probucol; Risk | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Probucol | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia.
Topics: Child; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Transplantation; Lovastatin; Male; Naphthalenes; Niacin; Plasma Exchange; Skin Diseases; Xanthomatosis | 1987 |
Comparison of six pharmacologic regimens for hypercholesterolemia.
Topics: Adult; Aged; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Retrospective Studies | 1987 |
[Drugs in hyperlipidemia].
Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypolipidemic Agents; Neomycin; Niacin | 1987 |
Addition to labeling of cholestyramine.
Topics: Cholestyramine Resin; Clofibrate; Diet Therapy; Drug Labeling; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Pentanoic Acids; Probucol; Thyroxine; United States; United States Food and Drug Administration | 1985 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Neomycin; Niacin; Pentanoic Acids; Probucol; Triglycerides | 1985 |
Treatment of homozygous familial hypercholesterolaemia: an informative sibship.
Topics: Adolescent; Age Factors; Arteriosclerosis; Cholestyramine Resin; Clofibrate; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Infant; Male; Middle Aged; Niacin | 1985 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Diabetes Complications; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Hypolipidemic Agents; Hypothyroidism; Kidney Diseases; Lipoproteins; Male; Neomycin; Niacin; Obesity; Pancreatitis; Xanthomatosis | 1985 |
Induction of peroxisomal enzymes and palmitoyl-CoA hydrolase in rats treated with cholestyramine and nicotinic acid.
Topics: Animals; Cholestyramine Resin; Enzyme Induction; Liver; Male; Microbodies; Niacin; Organ Size; Palmitoyl-CoA Hydrolase; Rats; Rats, Inbred Strains; Thiolester Hydrolases; Urate Oxidase | 1984 |
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Topics: Adolescent; Adult; Cerebrovascular Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Combined Modality Therapy; Dietary Fats; Drug Therapy, Combination; Germany, East; Humans; Hyperlipoproteinemias; Middle Aged; Myocardial Infarction; Niacin; Physical Exertion; Triglycerides | 1984 |
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Triglycerides; Valerates | 1983 |
Criteria for use of hypolipidemic agents in adults.
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Niacin; Risk Factors | 1994 |
Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Arteries; Blood Pressure; Body Mass Index; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Dietary Fats; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides; Ultrasonography; Weight Gain | 1993 |
New guidelines for managing hypercholesterolemia. National Cholesterol Education Program.
Topics: Algorithms; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxidoreductases; Risk Factors | 1993 |
[The treatment of atherosclerosis--drug therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Cholestyramine Resin; Humans; Middle Aged; Niacin | 1993 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Probucol | 1993 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
Choice of lipid-lowering drugs.
Topics: Cholestyramine Resin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Niacin | 1996 |
Choice of lipid-lowering drugs.
Topics: Animals; Cholestyramine Resin; Coronary Disease; Estrogen Replacement Therapy; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Niacin | 1998 |
Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992.
Topics: Adult; Aged; Blood Component Removal; Child; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Dextran Sulfate; Humans; Hypercholesterolemia; Immunosorbent Techniques; Lovastatin; Middle Aged; Niacin; Pilot Projects | 1993 |
Diagnosis, management and prevention of the common dyslipidaemias in South Africa--clinical guideline, 2000. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group.
Topics: Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Referral and Consultation; Risk Factors | 2000 |
Alterations in membrane-bound and cytoplasmic K-ras protein levels in mouse lung induced by treatment with lovastatin, cholestyramine, or niacin: effects are highly mouse strain dependent.
Topics: Animals; Body Weight; Cell Membrane; Cholesterol; Cholestyramine Resin; Cytoplasm; Genes, ras; Hypolipidemic Agents; Lovastatin; Lung; Mice; Mice, Inbred C57BL; Niacin; Triglycerides | 2002 |
Treatment with lovastatin, cholestyramine or niacin alters K-ras membrane association in mouse lung in a strain-dependent manner: results in females.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cell Membrane; Cholestyramine Resin; Cytosol; Female; Lipids; Lovastatin; Lung; Male; Mice; Mice, Inbred C57BL; Niacin; Proto-Oncogene Mas; ras Proteins; Sex Factors | 2003 |
Hormonal hypercholesterolemia in the dog: influence of niacin, niacinamide, benzmalecene, and cholestyramine resin.
Topics: Animals; Cholestyramine Resin; Dogs; Hypercholesterolemia; Ion Exchange Resins; Maleates; Niacin; Niacinamide; Nicotinic Acids | 1963 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Risk Factors; Treatment Outcome | 2004 |
Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin | 2005 |
Complementary care. How statin alternatives stack up. Some help control cholesterol; others are potentially harmful.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Fatty Alcohols; Humans; Niacin; Phytotherapy; Psyllium | 2005 |
Lipid testing and lipid-lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry.
Topics: Aged; Anticoagulants; Cholestyramine Resin; Clofibric Acid; Female; Hospital Records; Hospitalization; Hospitals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Ischemic Attack, Transient; Lipids; Male; Middle Aged; Models, Statistical; Niacin; Registries; Risk Factors; Stroke | 2006 |
Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung--importance of mouse strain.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; Body Weight; Cholesterol; Cholestyramine Resin; Electrophoresis, Agar Gel; Lovastatin; Lung; Male; Mannans; Mice; Mice, Inbred C57BL; Niacin; ras Proteins; Species Specificity | 2006 |
Supravalvular and valvular aortic stenosis in heterozygous familial hypercholesterolemia.
Topics: Adolescent; Aortic Stenosis, Supravalvular; Aortic Valve Stenosis; Atorvastatin; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Niacin; Pyrroles | 2007 |
Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis.
Topics: Cholestyramine Resin; Drug-Related Side Effects and Adverse Reactions; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Probucol | 2023 |